Global Phase II trial of NS-089／NCNP-02 for Duchenne muscular dystrophy

A discrete drug development theme involving the preparation for and continuation after initiation of a global Phase II trial of NS-089／NCNP-02 for Duchenne muscular dystrophy.

Companies1How many companies write about this.

Threads1One company can carry more than one thread here.

PeriodFY2023 →Last written FY2025-H1

Directionhelps1 helps · 0 hurts · 0 flat

Loading